Findings

What do systematic reviews say?

4,736 questions · 15,265 findings · 1,163 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,871 · 25.4%GRADE not reported 810 · 5.3%Very low 4,242 · 27.8%Low 3,879 · 25.4%Moderate 1,999 · 13.1%High 464 · 3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Antidepressants vs any other pharmacological intervention

Adverse events · women of any age, with PND up to 12 months

The review found no eligible studies for this question.

1 finding from 1 review

Antidepressant treatment for postnatal depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs any other pharmacological intervention

Depression response (early phase, < 5 weeks) · women of any age, with PND up to 12 months

1 finding from 1 review

Antidepressant treatment for postnatal depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Antidepressants vs any other pharmacological intervention

Depression severity (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months

1 finding from 1 review

Antidepressant treatment for postnatal depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Antidepressants vs any other pharmacological intervention

Acceptability ‐ total dropouts · women of any age, with PND up to 12 months

It is very uncertain whether antidepressants changes treatment acceptability ‐dropouts compared with any other pharmacological intervention (very low certainty).

1 finding from 1 review

Antidepressant treatment for postnatal depression 2021 · Cochrane Headline outcomes only
RR 1.74 [0.99, 3.06]
Studies not reported
Very low

Antidepressants vs any other pharmacological intervention

Child‐related outcomes · women of any age, with PND up to 12 months

The review found no eligible studies for this question.

1 finding from 1 review

Antidepressant treatment for postnatal depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention leads to higher BEV+IRI (1 RCT, 79 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 2.22 [1.19, 4.18]
1 study · 79 participants
High

Intervention not reported

BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 3.77 [2.25, 6.33]
1 study · 111 participants
High

Intervention not reported

BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 6.86 [2.55, 18.41]
1 study · 105 participants
High

Intervention not reported

Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1024 participants
GRADE not reported

Intervention not reported

BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 498 participants
GRADE not reported

Intervention not reported

FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 0.44 [0.11, 1.72]
1 study · 32 participants
GRADE not reported

Intervention not reported

BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.01 [0.33, 3.1]
1 study · 96 participants
Low

Intervention not reported

BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+ONA(1 RCT; 64 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.17 [0.57, 2.39]
1 study · 64 participants
Low

Intervention not reported

BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.27 [0.61, 2.66]
1 study · 58 participants
Low

Intervention not reported

BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 0.52 [0.69, 3.34]
2 studies · 83 participants
High

Intervention not reported

studies 1847 participants · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
19 studies · 1847 participants
GRADE not reported

Intervention not reported

CRFWVT (Rezūm) (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Intervention not reported

TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Intervention not reported

TIND (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Intervention not reported

TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

The review found no eligible studies for this question.

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found